Moneycontrol PRO
Black Friday Sale
Black Friday Sale
HomeNewscoronavirusIntranasal Covid vaccine: All you need to know about doses, prices and availability

Intranasal Covid vaccine: All you need to know about doses, prices and availability

The nasal vaccine will be ready for circulation to the public from the fourth week of January.

December 28, 2022 / 14:00 IST
Representative image

A single dose of iNCOVACC, the intranasal vaccine from Bharat Biotech that was approved as a part of the immunisation programme last week against the Covid-19 pandemic is priced at Rs 800 each, apart from the Goods and Services Tax for private hospitals. Slots for the same can now be booked on the CoWin portal.

The nasal vaccine will be ready for circulation to the public from the fourth week of January.

For mass procurement of the vaccine by the Centre as well as the state, Incovacc will be sold at a price of Rs 325 per dose.

The vaccine is being rolled out as a booster dose for people aged 18 and above.

iNCOVACC is the world’s very first intranasal vaccine for Covid-19 that has received approval for the primary two-dose schedule, as well as a heterogeneous booster dose, Bharat Biotech said.

COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more
Show

The intranasal vaccine, which was approved earlier both as a booster shot for those fully vaccinated with Covaxin or Covishield as well as a primary vaccine for a full two-dose course against Covid-19, would be available at private vaccination centres by the end of January.

“Bharat Biotech had reached out to us for price fixation of its intranasal vaccine and it has been approved now. The vaccine is going to be available in less than a month in private hospitals,” a senior government official said.

Read more: Bharat Biotech’s intranasal Covid-19 vaccine will cost Rs 800 plus 5% GST per dose to private hospitals

Moneycontrol News
first published: Dec 28, 2022 02:00 pm

Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Subscribe to Tech Newsletters

  • On Saturdays

    Find the best of Al News in one place, specially curated for you every weekend.

  • Daily-Weekdays

    Stay on top of the latest tech trends and biggest startup news.

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347